Skip to main content

Blog

PPMD Applauds FDA Launch of Rare Disease Innovation Hub — A Milestone for Rare Disease Patients

...

Capricor Therapeutics Announces Positive Skeletal Muscle and Cardiac Function Data from HOPE-2 OLE Study Data of Deramiocel (CAP-1002)

...

PPMD Convenes Leading Experts to Discuss Topics in Becker Care Ahead of 30th Annual Conference

...

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include New Cohort of Younger Patients

...

FDA Expands ELEVIDYS Label Indication for Ages 4 Years and Older

...

PAAC Travel Tips

...

Newborn Screening for Duchenne: PPMD’s Collaborative Future Planning Efforts

...

Cranbury Pharmaceuticals (Tris Pharma) Receives FDA Approval for First Generic Version of Emflaza® (deflazacort) for Duchenne

...

Build Your Own Care Binder at PPMD’s 30th Annual Conference

...

Pfizer Shares Update on Phase 3 Study of Investigational Mini-Dystrophin Gene Therapy

...